Lilly misses analyst estimates, lowers profit forecast

Back to TopCommentsE-mailPrintBookmark and Share

Third-quarter profit at Eli Lilly and Co. missed analysts' estimates, and the Indianapolis-based drugmaker lowered its profit forecast by 4 cents per share for the remainder of the year.

Shares in Lilly were down more than 2 percent at midday Wednesday, to $50.76 each.

Lilly earned $1.3 billion during the three months ended Sept. 30, up by 7 percent from the same period a year ago. But that boost was due largely to an early payoff from former drug-development partner Amylin Pharmaceuticals Inc.

Excluding the Amylin payments and other special items, Lilly’s profit would have fallen to $888 million, a whopping 29-percent decline from the same period last year. On that basis, earnings per share were 79 cents in the most recent quarter.

Wall Street analysts were expecting 83 cents per share, according to a survey by Thomson Reuters.

Lilly’s revenue also was below analysts’ forecasts. The company brought in $5.44 billion during the quarter, down 11 percent from the same quarter last year. Analysts were expecting $5.62 billion.

Lilly lowered its full-year profit forecast to a range of $3.68 per share to $3.78 per share. Larger asset impairment and restructuring costs shaved 4 cents from the forecast issued in August.

However, excluding all special gains or losses, Lilly still expects to earn from $3.30 per share to $3.40 per share, the same as it had forecast in August.

“Lilly reported a ho-hum quarter,” Mark Schoenebaum, an analyst with ISI Group in New York, said in a note to clients, according to Bloomberg News. “Marginally weak financial quarter, but nothing terrible.”

Lilly’s revenue has been falling because its former bestseller Zyprexa lost patent protection a year ago. Lilly has been trying to offset the loss of $2.5 billion in Zyprexa revenue so far this year by improving sales of other drugs.

In the third quarter, sales of the antidepressant Cymbalta, the osteoporosis drug Forteo and Lilly’s animal health products all grew 20 percent or more over the same quarter last year.

Lilly also received $1.26 billion from Amylin following Amylin's acquisition by New York-based Bristol-Myers Squibb Co. Lilly and Amylin had co-developed the diabetes drugs Byetta and Bydureon. But a dispute last year led to a break-up of their partnership.

Lilly’s shares fell Tuesday prior to the earnings announcement by less than 1 percentage point, to $51.91. The stock had been flat all year until Aug. 24, when Lilly announced its experimental Alzheiemer’s drug solanezumab had shown some positive effects on patients. Since then, Lilly’s shares have traded up 22 percent.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing